Praxis Precision Medicines (PRAX) Price & Analysis

Compare

648 Followers

PRAX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$26.70 - $91.83

Previous CloseN/A

Volume51.58K

Average Volume (3M)502.90K

Market Cap

$958.42M

Enterprise Value$602.50M

Total Cash (Recent Filing)$301.27M

Total Debt (Recent Filing)$755.00K

Price to Earnings (P/E)―

Beta1.54

Next Earnings

Nov 05, 2025

EPS Estimate

-3.38

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.31

Shares Outstanding21,045,780

10 Day Avg. Volume342,322

30 Day Avg. Volume502,900

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.63

Enterprise Value/Revenue77.59

Enterprise Value/Gross Profit78.53

Enterprise Value/Ebitda-2.26

Forecast

1Y Price Target

$113.63

Price Target Upside149.52% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Efficacy And SafetyVormatrigine's Phase 2 study in focal onset seizures demonstrated best-in-class efficacy with comparable safety, showing a 56.3% seizure reduction, which is better than cenobamate's.

Market PotentialAnalyst raised the price target for the stock to $115, reflecting increased confidence in vormatrigine's market potential and peak sales estimates.

Regulatory AdvancementBreakthrough Therapy Designation for relutrigine provides another validation of Praxis' emerging leadership in epilepsy and increases chances for approval.

Bears Say

Discontinuation RatesThe discontinuation rate of 23% was higher than expected, which is pressuring Praxis shares despite impressive efficacy.

Regulatory ChallengesRisks include regulatory challenges, as none of Praxis’ products is FDA-approved, and the company has never launched a product before.

Safety ConcernsSafety looked comparable to competition with 23% discontinuations, which put pressure on PRAX.

Praxis Precision Medicines News

Praxis Precision price target raised to $115 from $105 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Praxis Precision (PRAX) to $115 from $105 and keeps a...

26d ago

PRAX

Praxis Precision reports Q2 EPS ($3.31), consensus ($3.36)

“In the second quarter, we continued to make remarkable progress across our portfolio and believe we are positioned...

27d ago

PRAX

Praxis Precision announces topline results from Phase 2 RADIANT study

Praxis Precision (PRAX) Medicines announced topline results from the Phase 2 RADIANT study evaluating vormatrigine in patients with...

27d ago

PRAX

Praxis Precision Medicines’ Positive Earnings Call Highlights Vormatrigine Success

Praxis Precision Medicines, Inc. (($PRAX)) has held its Q2 earnings call. Read on for the main highlights of...

26d ago

PRAX

Praxis Precision Medicines Reports Promising Study Results

Praxis Precision Medicines, Inc. ( ($PRAX) ) has released its Q2 earnings. Here is a breakdown of the...

27d ago

PRAX

Promising Potential of Praxis Precision Medicines: Buy Rating Affirmed by Douglas Tsao

Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Praxis Precision Medicines and keeping the price...

27d ago

PRAX

Praxis Announces Positive Results from RADIANT Study

An update from Praxis Precision Medicines ( ($PRAX) ) is now available. On August 4, 2025, Praxis Precision...

27d ago

PRAX

Positive Phase 2 Results for Praxis Precision Medicines’ Vormatrigine Drive Buy Rating

Analyst Ami Fadia from Needham maintained a Buy rating on Praxis Precision Medicines and keeping the price target...

27d ago

PRAX

PRAX Upcoming Earnings Report: What to Expect?

Praxis Precision Medicines, Inc. (PRAX) is scheduled to report 2nd quarter earnings on 08/04/2025, before the market opens....

29d ago

PRAX

Praxis Precision Medicines Gains FDA Breakthrough Designation

An announcement from Praxis Precision Medicines ( ($PRAX) ) is now available. On July 17, 2025, Praxis Precision...

2M ago

PRAX

Praxis Precision receives FDA Breakthrough Therapy Designation for relutrigine

Praxis Precision (PRAX) Medicines announced that the U.S. Food and Drug Administration has granted BTD for relutrigine, a...

2M ago

PRAX

3 Best Stocks to Buy Now, 7/15/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

2M ago

MLYS

PRAX

3 Best Stocks to Buy Now, 7/11/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

2M ago

BABA

BTDR

Praxis Precision price target raised to $115 from $97 at Oppenheimer

Oppenheimer raised the firm’s price target on Praxis Precision (PRAX) to $115 from $97 and keeps an Outperform...

2M ago

PRAX

PRAX FAQ

What was Praxis Precision Medicines’s price range in the past 12 months?

Praxis Precision Medicines lowest stock price was $26.70 and its highest was $91.83 in the past 12 months.

What is Praxis Precision Medicines’s market cap?

Praxis Precision Medicines’s market cap is $958.42M.

When is Praxis Precision Medicines’s upcoming earnings report date?

Praxis Precision Medicines’s upcoming earnings report date is Nov 05, 2025 which is in 66 days.

How were Praxis Precision Medicines’s earnings last quarter?

Praxis Precision Medicines released its earnings results on Aug 04, 2025. The company reported -$3.31 earnings per share for the quarter, missing the consensus estimate of -$3.247 by -$0.063.

Is Praxis Precision Medicines overvalued?

According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Praxis Precision Medicines pay dividends?

Praxis Precision Medicines does not currently pay dividends.

What is Praxis Precision Medicines’s EPS estimate?

Praxis Precision Medicines’s EPS estimate is -3.38.

How many shares outstanding does Praxis Precision Medicines have?

Praxis Precision Medicines has 21,045,780 shares outstanding.

What happened to Praxis Precision Medicines’s price movement after its last earnings report?

Praxis Precision Medicines reported an EPS of -$3.31 in its last earnings report, missing expectations of -$3.247. Following the earnings report the stock price went down -5.546%.

Which hedge fund is a major shareholder of Praxis Precision Medicines?

Currently, no hedge funds are holding shares in PRAX

Praxis Precision Medicines Stock Smart Score

Neutral

Fundamentals

Return on Equity

-60.98%

Trailing 12-Months

Asset Growth

2.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Praxis Precision Medicines

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines (PRAX) Earnings & Revenues

Historic Earnings Reports

PRAX Company Deck

PRAX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant advancements in the efficacy of vormatrigine, strong execution of clinical trials, and a robust financial position. However, challenges remain in managing discontinuation rates and background therapy interactions.View all PRAX earnings summaries

PRAX Stock 12 Month Forecast

Average Price Target

$113.63

▲(149.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","271":"$271","91.75":"$91.8","151.5":"$151.5","211.25":"$211.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$270.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":113.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$113.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,91.75,151.5,211.25,271],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.09,70.69846153846154,87.30692307692308,103.91538461538461,120.52384615384615,137.13230769230768,153.74076923076922,170.34923076923076,186.9576923076923,203.56615384615384,220.17461538461538,236.78307692307692,253.39153846153843,{"y":270,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.09,58.67,63.25,67.83,72.41,76.99,81.57,86.15,90.72999999999999,95.31,99.88999999999999,104.47,109.05,{"y":113.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,54.09,52.46769230769231,50.84538461538462,49.223076923076924,47.60076923076923,45.97846153846154,44.356153846153845,42.73384615384616,41.11153846153846,39.48923076923077,37.86692307692307,36.244615384615386,34.62230769230769,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.15,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.43,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.06,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.82,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >